Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Nuvo Pharmaceuticals Inc MRVFF

Nuvo Pharmaceuticals Inc is a Canadian focused healthcare company doing business as Miravo Healthcare with global reach and a diversified portfolio of commercial products. Its product targets several therapeutic areas, including pain, allergy, and dermatology. The company's strategy is to in-license and acquire growth-oriented, complementary products for Canadian and international markets.


OTCQX:MRVFF - Post by User

Comment by lscfaon Nov 01, 2019 5:26pm
145 Views
Post# 30299533

RE:RE:WHY the sell off

RE:RE:WHY the sell off

Investors are getting confused with distorted accounting no.s and distorted cash flow no.s. Must rely on adj ebitda no.s......
 

 

 

Q3

Q2

CFO

6603

1457

Cash INT paid

1479

1517

Billed assets *

66

2498

Total

8148

5472

vs. Adj ebitda 

7784

5663

 

 

 

* Amounts billed to customers for existing contract assets

 

 

 



lscfa wrote:

I think people are looking at the net income line and seeing that Q3 is down from Q2 but Q2 had a bunch of one-time non-cash items. Co. should change its presentation and show an operating income line......

 

 

 

Q3

Q2

Rev

18,823

16,580

Cogs

(7,499)

(6,931)

Marketing exp

(1,955)

(3,043)

G&A

(3,584)

(5,125)

Op inc.

5,785

1,481

Cash INT exp

(1,567)

(1,555)

Cash income

4,218

(74)

Non-cash inc

56

6,966

Ebit

4,274

6,892

Tax

151

(96)

Net income

4,425

6,796

 

 

 

Gross margin

60.2%

58.2%

 

 

 

Non cash income (expenses):

 

 

Amort finance fees

(1,599)

(512)

Amort intangible

(2,108)

(2,181)

Deriv gain

3,890

32,641

Conting. Gain

205

507

Asset impairment

0

(23,621)

Fx loss (gain)

(201)

740

Other losses

(131)

(608)

 

56

6,966

 


 

 

midard wrote: Market cap was almost the same as earning yesterday. who is anonimous?

 

 



<< Previous
Bullboard Posts
Next >>